{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:39:39Z","timestamp":1793281179122,"version":"4.5.0"},"reference-count":296,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41573-026-01517-0","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:11:38Z","timestamp":1787562698000},"page":"829-854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting CDKs in the RNAPII transcription cycle"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9873-8457","authenticated-orcid":false,"given":"Robert P.","family":"Fisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7718-5002","authenticated-orcid":false,"given":"Matthias","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"1517_CR1","unstructured":"Morgan, D. O. The Cell Cycle: Principles of Control (New Science Press, 2007)."},{"key":"1517_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/gb4184","volume":"15","author":"M Malumbres","year":"2014","unstructured":"Malumbres, M. Cyclin-dependent kinases. Genome Biol. 15, 122 (2014).","journal-title":"Genome Biol."},{"key":"1517_CR3","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.4161\/cc.20758","volume":"11","author":"KA Merrick","year":"2012","unstructured":"Merrick, K. A. & Fisher, R. P. Why minimal is not optimal: driving the mammalian cell cycle \u2014 and drug discovery \u2014 with a physiologic CDK control network. Cell Cycle 11, 2600\u20132605 (2012).","journal-title":"Cell Cycle"},{"key":"1517_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw2106","volume":"366","author":"KZ Guiley","year":"2019","unstructured":"Guiley, K. Z. et al. p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition. Science 366, eaaw2106 (2019).","journal-title":"Science"},{"key":"1517_CR5","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41589-020-0563-4","volume":"16","author":"PK Parua","year":"2020","unstructured":"Parua, P. K. & Fisher, R. P. Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors. Nat. Chem. Biol. 16, 716\u2013724 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"1517_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","volume":"20","author":"MM Attwood","year":"2021","unstructured":"Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S. & Schioth, H. B. Trends in kinase drug discovery: targets, indications and inhibitor design. Nat. Rev. Drug Discov. 20, 839\u2013861 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1517_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2022.102186","volume":"70","author":"KC Clopper","year":"2022","unstructured":"Clopper, K. C. & Taatjes, D. J. Chemical inhibitors of transcription-associated kinases. Curr. Opin. Chem. Biol. 70, 102186 (2022).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"1517_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41568-021-00411-8","volume":"22","author":"SJ Vervoort","year":"2022","unstructured":"Vervoort, S. J. et al. Targeting transcription cycles in cancer. Nat. Rev. Cancer 22, 5\u201324 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"1517_CR9","doi-asserted-by":"publisher","first-page":"8456","DOI":"10.1021\/cr400071f","volume":"113","author":"D Eick","year":"2013","unstructured":"Eick, D. & Geyer, M. The RNA polymerase II carboxy-terminal domain (CTD) code. Chem. Rev. 113, 8456\u20138490 (2013).","journal-title":"Chem. Rev."},{"key":"1517_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.molcel.2009.10.019","volume":"36","author":"S Buratowski","year":"2009","unstructured":"Buratowski, S. Progression through the RNA polymerase II CTD cycle. Mol. Cell 36, 541\u2013546 (2009).","journal-title":"Mol. Cell"},{"key":"1517_CR11","doi-asserted-by":"publisher","first-page":"146","DOI":"10.4161\/trns.25146","volume":"4","author":"M Sans\u00f3","year":"2013","unstructured":"Sans\u00f3, M. & Fisher, R. P. Pause, play, repeat: CDKs push RNAP II\u2019s buttons. Transcription 4, 146\u2013152 (2013).","journal-title":"Transcription"},{"key":"1517_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nrg3662","volume":"15","author":"DL Bentley","year":"2014","unstructured":"Bentley, D. L. Coupling mRNA processing with transcription in time and space. Nat. Rev. Genet. 15, 163\u2013175 (2014).","journal-title":"Nat. Rev. Genet."},{"key":"1517_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0968-0004(90)90236-5","volume":"15","author":"JL Corden","year":"1990","unstructured":"Corden, J. L. Tails of RNA polymerase II. Trends Biochem. Sci. 15, 383\u2013387 (1990).","journal-title":"Trends Biochem. Sci."},{"key":"1517_CR14","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nsb0903-679","volume":"10","author":"S Buratowski","year":"2003","unstructured":"Buratowski, S. The CTD code. Nat. Struct. Biol. 10, 679\u2013680 (2003).","journal-title":"Nat. Struct. Biol."},{"key":"1517_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.tig.2008.03.008","volume":"24","author":"S Egloff","year":"2008","unstructured":"Egloff, S. & Murphy, S. Cracking the RNA polymerase II CTD code. Trends Genet. 24, 280\u2013288 (2008).","journal-title":"Trends Genet."},{"key":"1517_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molcel.2011.05.024","volume":"43","author":"B Schwer","year":"2011","unstructured":"Schwer, B. & Shuman, S. Deciphering the RNA polymerase II CTD code in fission yeast. Mol. Cell 43, 311\u2013318 (2011).","journal-title":"Mol. Cell"},{"key":"1517_CR17","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41594-021-00613-6","volume":"28","author":"AC Schier","year":"2021","unstructured":"Schier, A. C. & Taatjes, D. J. Everything at once: cryo-EM yields remarkable insights into human RNA polymerase II transcription. Nat. Struct. Mol. Biol. 28, 540\u2013543 (2021).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1517_CR18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nsmb.3285","volume":"23","author":"J Zaborowska","year":"2016","unstructured":"Zaborowska, J., Egloff, S. & Murphy, S. The Pol II CTD: new twists in the tail. Nat. Struct. Mol. Biol. 23, 771\u2013777 (2016).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1517_CR19","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.celrep.2016.03.030","volume":"15","author":"ZC Poss","year":"2016","unstructured":"Poss, Z. C. et al. Identification of Mediator kinase substrates in human cells using cortistatin A and quantitative phosphoproteomics. Cell Rep. 15, 436\u2013450 (2016).","journal-title":"Cell Rep"},{"key":"1517_CR20","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.1128\/MCB.00637-09","volume":"29","author":"K Glover-Cutter","year":"2009","unstructured":"Glover-Cutter, K. et al. TFIIH-associated CDK7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II. Mol. Cell Biol. 29, 5455\u20135464 (2009).","journal-title":"Mol. Cell Biol."},{"key":"1517_CR21","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1128\/MCB.06657-11","volume":"32","author":"CV St Amour","year":"2012","unstructured":"St Amour, C. V. et al. Separate domains of fission yeast CDK9 (P-TEFb) are required for capping enzyme recruitment and primed (Ser7-phosphorylated) Rpb1 carboxyl-terminal domain substrate recognition. Mol. Cell Biol. 32, 2372\u20132383 (2012).","journal-title":"Mol. Cell Biol."},{"key":"1517_CR22","doi-asserted-by":"publisher","first-page":"5812","DOI":"10.1073\/pnas.0611505104","volume":"104","author":"EI Kanin","year":"2007","unstructured":"Kanin, E. I. et al. Chemical inhibition of the TFIIH-associated kinase CDK7\/Kin28 does not impair global mRNA synthesis. Proc. Natl Acad. Sci. USA 104, 5812\u20135817 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1517_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.molcel.2009.04.016","volume":"34","author":"MS Akhtar","year":"2009","unstructured":"Akhtar, M. S. et al. TFIIH kinase places bivalent marks on the carboxy-terminal domain of RNA polymerase II. Mol. Cell 34, 387\u2013393 (2009).","journal-title":"Mol. Cell"},{"key":"1517_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/21541264.2018.1553483","volume":"10","author":"RP Fisher","year":"2019","unstructured":"Fisher, R. P. CDK7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery. Transcription 10, 47\u201356 (2019).","journal-title":"Transcription"},{"key":"1517_CR25","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/j.molcel.2024.05.007","volume":"84","author":"T Velychko","year":"2024","unstructured":"Velychko, T. et al. CDK7 kinase activity promotes RNA polymerase II promoter escape by facilitating initiation factor release. Mol. Cell 84, 2287\u20132303.e2210 (2024).","journal-title":"Mol. Cell"},{"key":"1517_CR26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.molcel.2014.03.024","volume":"54","author":"KH Wong","year":"2014","unstructured":"Wong, K. H., Jin, Y. & Struhl, K. TFIIH phosphorylation of the Pol II CTD stimulates Mediator dissociation from the preinitiation complex and promoter escape. Mol. Cell 54, 601\u2013612 (2014).","journal-title":"Mol. Cell"},{"key":"1517_CR27","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2015.06.032","volume":"59","author":"KA Nilson","year":"2015","unstructured":"Nilson, K. A. et al. THZ1 reveals roles for CDK7 in co-transcriptional capping and pausing. Mol. Cell 59, 576\u2013587 (2015).","journal-title":"Mol. Cell"},{"key":"1517_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05923-w","volume":"9","author":"M Noe Gonzalez","year":"2018","unstructured":"Noe Gonzalez, M., Sato, S., Tomomori-Sato, C., Conaway, J. W. & Conaway, R. C. CTD-dependent and -independent mechanisms govern co-transcriptional capping of Pol II transcripts. Nat. Commun. 9, 3392 (2018).","journal-title":"Nat. Commun."},{"key":"1517_CR29","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrg3293","volume":"13","author":"K Adelman","year":"2012","unstructured":"Adelman, K. & Lis, J. T. Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans. Nat. Rev. Genet. 13, 720\u2013731 (2012).","journal-title":"Nat. Rev. Genet."},{"key":"1517_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adt5885","volume":"11","author":"Y Aoi","year":"2025","unstructured":"Aoi, Y. et al. SPT5 regulates RNA polymerase II stability via Cullin 3-ARMC5 recognition. Sci. Adv. 11, eadt5885 (2025).","journal-title":"Sci. Adv."},{"key":"1517_CR31","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1016\/j.molcel.2024.10.012","volume":"84","author":"D Blears","year":"2024","unstructured":"Blears, D. et al. Redundant pathways for removal of defective RNA polymerase II complexes at a promoter-proximal pause checkpoint. Mol. Cell 84, 4790\u20134807 (2024).","journal-title":"Mol. Cell"},{"key":"1517_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03006-4","volume":"9","author":"GT Booth","year":"2018","unstructured":"Booth, G. T., Parua, P. K., Sanso, M., Fisher, R. P. & Lis, J. T. CDK9 regulates a promoter-proximal checkpoint to modulate RNA polymerase II elongation rate in fission yeast. Nat. Commun. 9, 543 (2018).","journal-title":"Nat. Commun."},{"key":"1517_CR33","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1016\/j.molcel.2024.11.024","volume":"84","author":"R Cacioppo","year":"2024","unstructured":"Cacioppo, R. et al. CRL3ARMC5 ubiquitin ligase and Integrator phosphatase form parallel mechanisms to control early stages of RNA Pol II transcription. Mol. Cell 84, 4808\u20134823 (2024).","journal-title":"Mol. Cell"},{"key":"1517_CR34","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1101\/gad.325142.119","volume":"33","author":"L Core","year":"2019","unstructured":"Core, L. & Adelman, K. Promoter-proximal pausing of RNA polymerase II: a nexus of gene regulation. Genes Dev. 33, 960\u2013982 (2019).","journal-title":"Genes Dev."},{"key":"1517_CR35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1146\/annurev-biochem-051424-053703","volume":"95","author":"U Hyder","year":"2026","unstructured":"Hyder, U. & Bentley, D. L. The promoter-proximal pause: a decision point governing RNA polymerase II fate. Ann. Rev. Biochem. 95, 221\u2013246 (2026).","journal-title":"Ann. Rev. Biochem."},{"key":"1517_CR36","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.02407","volume":"3","author":"I Jonkers","year":"2014","unstructured":"Jonkers, I., Kwak, H. & Lis, J. T. Genome-wide dynamics of Pol II elongation and its interplay with promoter proximal pausing, chromatin, and exons. eLife 3, e02407 (2014).","journal-title":"eLife"},{"key":"1517_CR37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrm3953","volume":"16","author":"I Jonkers","year":"2015","unstructured":"Jonkers, I. & Lis, J. T. Getting up to speed with transcription elongation by RNA polymerase II. Nat. Rev. Mol. Cell Biol. 16, 167\u2013177 (2015).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1517_CR38","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41586-018-0442-2","volume":"560","author":"SM Vos","year":"2018","unstructured":"Vos, S. M., Farnung, L., Urlaub, H. & Cramer, P. Structure of paused transcription complex Pol II\u2013DSIF\u2013NELF. Nature 560, 601\u2013606 (2018).","journal-title":"Nature"},{"key":"1517_CR39","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nrm.2017.10","volume":"18","author":"KM Harlen","year":"2017","unstructured":"Harlen, K. M. & Churchman, L. S. The code and beyond: transcription regulation by the RNA polymerase II carboxy-terminal domain. Nat. Rev. Mol. Cell Biol. 18, 263\u2013273 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1517_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2024.168845","volume":"437","author":"L Farnung","year":"2025","unstructured":"Farnung, L. Chromatin transcription elongation \u2014 a structural perspective. J. Mol. Biol. 437, 168845 (2025).","journal-title":"J. Mol. Biol."},{"key":"1517_CR41","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.1007\/s00018-021-03878-8","volume":"78","author":"S Egloff","year":"2021","unstructured":"Egloff, S. CDK9 keeps RNA polymerase II on track. Cell Mol. Life Sci. 78, 5543\u20135567 (2021).","journal-title":"Cell Mol. Life Sci."},{"key":"1517_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18173-6","volume":"11","author":"PK Parua","year":"2020","unstructured":"Parua, P. K., Kalan, S., Benjamin, B., Sans\u00f3, M. & Fisher, R. P. Distinct CDK9-phosphatase switches act at the beginning and end of elongation by RNA polymerase II. Nat. Commun. 11, 4338 (2020).","journal-title":"Nat. Commun."},{"key":"1517_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13931-7","volume":"11","author":"I Sen","year":"2020","unstructured":"Sen, I. et al. DAF-16\/FOXO requires protein phosphatase 4 to initiate transcription of stress resistance and longevity promoting genes. Nat. Commun. 11, 138 (2020).","journal-title":"Nat. Commun."},{"key":"1517_CR44","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.molcel.2020.08.016","volume":"80","author":"KL Huang","year":"2020","unstructured":"Huang, K. L. et al. Integrator recruits protein phosphatase 2A to prevent pause release and facilitate transcription termination. Mol. Cell 80, 345 (2020).","journal-title":"Mol. Cell"},{"key":"1517_CR45","doi-asserted-by":"publisher","first-page":"eabb5872","DOI":"10.1126\/science.abb5872","volume":"370","author":"H Zheng","year":"2020","unstructured":"Zheng, H. et al. Identification of Integrator\u2013PP2A complex (INTAC), an RNA polymerase II phosphatase. Science 370, eabb5872 (2020).","journal-title":"Science"},{"key":"1517_CR46","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1016\/j.cell.2021.04.022","volume":"184","author":"SJ Vervoort","year":"2021","unstructured":"Vervoort, S. J. et al. The PP2A\u2013Integrator\u2013CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. Cell 184, 3143\u20133162.e3132 (2021). This study revealed opposing functions of CDK9 and PP2A in RNAPII transcription, and potential therapeutic synergy between CDK9-inhibiting and PP2A-activating small molecules.","journal-title":"Cell"},{"key":"1517_CR47","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2022.12.006","volume":"83","author":"K Fujinaga","year":"2023","unstructured":"Fujinaga, K., Huang, F. & Peterlin, B. M. P-TEFb: the master regulator of transcription elongation. Mol. Cell 83, 393\u2013403 (2023).","journal-title":"Mol. Cell"},{"key":"1517_CR48","doi-asserted-by":"publisher","first-page":"7527","DOI":"10.1093\/nar\/gkw585","volume":"44","author":"AJC Quaresma","year":"2016","unstructured":"Quaresma, A. J. C., Bugai, A. & Barboric, M. Cracking the control of RNA polymerase II elongation by 7SK snRNP and P-TEFb. Nucleic Acids Res. 44, 7527\u20137539 (2016).","journal-title":"Nucleic Acids Res."},{"key":"1517_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1201","volume":"13","author":"D Blazek","year":"2023","unstructured":"Blazek, D. Therapeutic potential of CDK11 in cancer. Clin. Transl. Med. 13, e1201 (2023).","journal-title":"Clin. Transl. Med."},{"key":"1517_CR50","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1016\/j.molcel.2025.08.001","volume":"85","author":"JR Devlin","year":"2025","unstructured":"Devlin, J. R. et al. A CDK11-dependent RNA polymerase II pause-checkpoint precedes CDK9-mediated transition to transcriptional elongation. Mol. Cell 85, 3256\u20133274.e3214 (2025). This study revealed a new function of CDK11 \u2014 and a novel checkpoint in RNAPII transcription \u2014 upstream of CDK9-dependent release from the canonical promoter-proximal pause.","journal-title":"Mol. Cell"},{"key":"1517_CR51","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.molcel.2019.09.031","volume":"76","author":"MA Cortazar","year":"2019","unstructured":"Cortazar, M. A. et al. Control of RNA Pol II speed by PNUTS\u2013PP1 and Spt5 dephosphorylation facilitates termination by a \u201csitting duck torpedo\u201d mechanism. Mol. Cell 76, 896\u2013908.e894 (2019).","journal-title":"Mol. Cell"},{"key":"1517_CR52","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201847592","volume":"20","author":"AP Chirackal Manavalan","year":"2019","unstructured":"Chirackal Manavalan, A. P. et al. CDK12 controls G1\/S progression by regulating RNAPII processivity at core DNA replication genes. EMBO Rep. 20, e47592 (2019).","journal-title":"EMBO Rep."},{"key":"1517_CR53","doi-asserted-by":"publisher","first-page":"eaaz5041","DOI":"10.1126\/sciadv.aaz5041","volume":"6","author":"Z Fan","year":"2020","unstructured":"Fan, Z. et al. CDK13 cooperates with CDK12 to control global RNA polymerase II processivity. Sci. Adv. 6, eaaz5041 (2020).","journal-title":"Sci. Adv."},{"key":"1517_CR54","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1101\/gad.269589.115","volume":"30","author":"M Sanso","year":"2016","unstructured":"Sanso, M. et al. P-TEFb regulation of transcription termination factor Xrn2 revealed by a chemical genetic screen for CDK9 substrates. Genes Dev. 30, 117\u2013131 (2016).","journal-title":"Genes Dev."},{"key":"1517_CR55","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41586-018-0214-z","volume":"558","author":"PK Parua","year":"2018","unstructured":"Parua, P. K. et al. A CDK9\u2013PP1 switch regulates the elongation-termination transition of RNA polymerase II. Nature 558, 460\u2013464 (2018).","journal-title":"Nature"},{"key":"1517_CR56","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.celrep.2018.09.007","volume":"25","author":"T Kecman","year":"2018","unstructured":"Kecman, T. et al. Elongation\/termination factor exchange mediated by PP1 phosphatase orchestrates transcription termination. Cell Rep. 25, 259\u2013269.e255 (2018).","journal-title":"Cell Rep."},{"key":"1517_CR57","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s42003-022-03214-1","volume":"5","author":"Z Liu","year":"2022","unstructured":"Liu, Z. et al. TOX4 facilitates promoter-proximal pausing and C-terminal domain dephosphorylation of RNA polymerase II in human cells. Commun. Biol. 5, 300 (2022).","journal-title":"Commun. Biol."},{"key":"1517_CR58","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1128\/MCB.00247-12","volume":"32","author":"NJ Fuda","year":"2012","unstructured":"Fuda, N. J. et al. Fcp1 dephosphorylation of the RNA polymerase II C-terminal domain is required for efficient transcription of heat shock genes. Mol. Cell. Biol. 32, 3428\u20133437 (2012).","journal-title":"Mol. Cell. Biol."},{"key":"1517_CR59","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0092-8674(95)90233-3","volume":"83","author":"RP Fisher","year":"1995","unstructured":"Fisher, R. P., Jin, P., Chamberlin, H. M. & Morgan, D. O. Alternative mechanisms of CAK assembly require an assembly factor or an activating kinase. Cell 83, 47\u201357 (1995).","journal-title":"Cell"},{"key":"1517_CR60","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1093\/emboj\/20.14.3749","volume":"20","author":"S Larochelle","year":"2001","unstructured":"Larochelle, S. et al. T-loop phosphorylation stabilizes the CDK7\u2013cyclin H\u2013MAT1 complex in vivo and regulates its CTD kinase activity. EMBO J. 20, 3749\u20133759 (2001).","journal-title":"EMBO J."},{"key":"1517_CR61","doi-asserted-by":"publisher","first-page":"5608","DOI":"10.1002\/j.1460-2075.1995.tb00248.x","volume":"14","author":"J-P Tassan","year":"1995","unstructured":"Tassan, J.-P. et al. In vitro assembly of a functional human cdk7\/cyclin H complex requires MAT1, a novel 36 kD RING finger protein. EMBO J. 14, 5608\u20135617 (1995).","journal-title":"EMBO J."},{"key":"1517_CR62","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1093\/emboj\/16.7.1638","volume":"16","author":"KY Yankulov","year":"1997","unstructured":"Yankulov, K. Y. & Bentley, D. L. Regulation of CDK7 substrate specificity by MAT1 and TFIIH. EMBO J. 16, 1638\u20131646 (1997).","journal-title":"EMBO J."},{"key":"1517_CR63","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2023114051","volume":"42","author":"C Wang","year":"2023","unstructured":"Wang, C. et al. CDK11 requires a critical activator SAP30BP to regulate pre-mRNA splicing. EMBO J. 42, e114051 (2023).","journal-title":"EMBO J."},{"key":"1517_CR64","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1016\/j.molcel.2025.04.012","volume":"85","author":"D Lopez Martinez","year":"2025","unstructured":"Lopez Martinez, D. et al. PAF1c-mediated activation of CDK12\/13 kinase activity is critical for CTD phosphorylation and transcript elongation. Mol. Cell 85, 1952\u20131967.e1958 (2025).","journal-title":"Mol. Cell"},{"key":"1517_CR65","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1128\/MCB.00993-08","volume":"29","author":"MT Knuesel","year":"2009","unstructured":"Knuesel, M. T., Meyer, K. D., Donner, A. J., Espinosa, J. M. & Taatjes, D. J. The human CDK8 subcomplex is a histone kinase that requires Med12 for activity and can function independently of Mediator. Mol. Cell Biol. 29, 650\u2013661 (2009).","journal-title":"Mol. Cell Biol."},{"key":"1517_CR66","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nature14904","volume":"526","author":"HE Pelish","year":"2015","unstructured":"Pelish, H. E. et al. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature 526, 273\u2013276 (2015). This paper shows that cortistatin A selectively inhibits Mediator kinases and has anti-leukaemic activity in acute myeloid leukaemia cell lines.","journal-title":"Nature"},{"key":"1517_CR67","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.celrep.2017.10.058","volume":"21","author":"MD Galbraith","year":"2017","unstructured":"Galbraith, M. D. et al. CDK8 kinase activity promotes glycolysis. Cell Rep. 21, 1495\u20131506 (2017).","journal-title":"Cell Rep."},{"key":"1517_CR68","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.molcel.2019.07.034","volume":"76","author":"I Steinparzer","year":"2019","unstructured":"Steinparzer, I. et al. Transcriptional responses to IFN-\u03b3 require Mediator kinase-dependent pause release and mechanistically distinct CDK8 and CDK19 functions. Mol. Cell 76, 485\u2013499 (2019).","journal-title":"Mol. Cell"},{"key":"1517_CR69","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1002\/j.1460-2075.1993.tb05980.x","volume":"12","author":"D Fesquet","year":"1993","unstructured":"Fesquet, D. et al. The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin-dependent kinases (CDKs) through phosphorylation of Thr161 and its homologues. EMBO J. 12, 3111\u20133121 (1993).","journal-title":"EMBO J."},{"key":"1517_CR70","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/0092-8674(94)90535-5","volume":"78","author":"RP Fisher","year":"1994","unstructured":"Fisher, R. P. & Morgan, D. O. A novel cyclin associates with MO15\/CDK7 to form the CDK-activating kinase. Cell 78, 713\u2013724 (1994).","journal-title":"Cell"},{"key":"1517_CR71","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/371254a0","volume":"371","author":"TP M\u00e4kel\u00e4","year":"1994","unstructured":"M\u00e4kel\u00e4, T. P. et al. A cyclin associated with the CDK-activating kinase MO15. Nature 371, 254\u2013257 (1994).","journal-title":"Nature"},{"key":"1517_CR72","first-page":"7265","volume":"14","author":"M Matsuoka","year":"1994","unstructured":"Matsuoka, M., Kato, J., Fisher, R. P., Morgan, D. O. & Sherr, C. J. Activation of cyclin-dependent kinase-4 (CDK4) by mouse MO15-associated kinase. Mol. Cell Biol. 14, 7265\u20137275 (1994).","journal-title":"Mol. Cell Biol."},{"key":"1517_CR73","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1002\/j.1460-2075.1993.tb05981.x","volume":"12","author":"RYC Poon","year":"1993","unstructured":"Poon, R. Y. C., Yamashita, K., Adamczewski, J. P., Hunt, T. & Shuttleworth, J. The cdc2-related protein p40MO15 is the catalytic subunit of a protein kinase that can activate p33cdk2 and p34cdc2. EMBO J. 12, 3123\u20133132 (1993).","journal-title":"EMBO J."},{"key":"1517_CR74","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1002\/j.1460-2075.1993.tb05982.x","volume":"12","author":"MJ Solomon","year":"1993","unstructured":"Solomon, M. J., Harper, J. W. & Shuttleworth, J. CAK, the p34cdc2 activating kinase, contains a protein identical or closely related to p40MO15. EMBO J. 12, 3133\u20133142 (1993).","journal-title":"EMBO J."},{"key":"1517_CR75","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1242\/jcs.107.10.2789","volume":"107","author":"RYC Poon","year":"1994","unstructured":"Poon, R. Y. C. et al. Cell cycle regulation of the p34cdc2\/p33cdk2-activating kinase p40MO15. J. Cell Sci. 107, 2789\u20132799 (1994).","journal-title":"J. Cell Sci."},{"key":"1517_CR76","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/0092-8674(94)90040-X","volume":"79","author":"WJ Feaver","year":"1994","unstructured":"Feaver, W. J., Svejstrup, J. Q., Henry, N. L. & Kornberg, R. D. Relationship of CDK-activating kinase and RNA polymerase II CTD kinase TFIIH\/TFIIK. Cell 79, 1103\u20131109 (1994).","journal-title":"Cell"},{"key":"1517_CR77","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/0092-8674(94)90039-6","volume":"79","author":"R Roy","year":"1994","unstructured":"Roy, R. et al. The MO15 cell cycle kinase is associated with the TFIIH transcription-DNA repair factor. Cell 79, 1093\u20131101 (1994).","journal-title":"Cell"},{"key":"1517_CR78","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/374280a0","volume":"374","author":"H Serizawa","year":"1995","unstructured":"Serizawa, H. et al. Association of CDK-activating kinase subunits with transcription factor TFIIH. Nature 374, 280\u2013282 (1995).","journal-title":"Nature"},{"key":"1517_CR79","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/374283a0","volume":"374","author":"R Shiekhattar","year":"1995","unstructured":"Shiekhattar, R. et al. CDK-activating kinase complex is a component of human transcription factor TFIIH. Nature 374, 283\u2013287 (1995).","journal-title":"Nature"},{"key":"1517_CR80","doi-asserted-by":"publisher","first-page":"22849","DOI":"10.1073\/pnas.2009627117","volume":"117","author":"BJ Greber","year":"2020","unstructured":"Greber, B. J. et al. The cryoelectron microscopy structure of the human CDK-activating kinase. Proc. Natl Acad. Sci. USA 117, 22849\u201322857 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1517_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50891-z","volume":"15","author":"R D\u00fcster","year":"2024","unstructured":"D\u00fcster, R. et al. Structural basis of CDK7 activation by dual T-loop phosphorylation. Nat. Commun. 15, 6597 (2024).","journal-title":"Nat. Commun."},{"key":"1517_CR82","doi-asserted-by":"publisher","first-page":"eadq5091","DOI":"10.1126\/scitranslmed.adq5091","volume":"16","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. Disrupting the RNA polymerase II transcription cycle through CDK7 inhibition ameliorates inflammatory arthritis. Sci. Transl. Med. 16, eadq5091 (2024). This study shows that CDK7 inhibition specifically suppresses proinflammatory gene expression, which ameliorates disease symptoms in mouse models of rheumatoid arthritis.","journal-title":"Sci. Transl. Med."},{"key":"1517_CR83","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nature13393","volume":"511","author":"N Kwiatkowski","year":"2014","unstructured":"Kwiatkowski, N. et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 511, 616\u2013620 (2014). This is, to our knowledge, the first description of a specific inhibitor targeting a transcriptional CDK: covalent binding of THZ1 to CDK7 opened up the field for the study of transcriptional CDK inhibitors in oncology.","journal-title":"Nature"},{"key":"1517_CR84","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/nsmb.2399","volume":"19","author":"S Larochelle","year":"2012","unstructured":"Larochelle, S. et al. Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat. Struct. Mol. Biol. 19, 1108\u20131115 (2012).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1517_CR85","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.molcel.2011.05.030","volume":"43","author":"D Grohmann","year":"2011","unstructured":"Grohmann, D. et al. The initiation factor TFE and the elongation factor Spt4\/5 compete for the RNAP clamp during transcription initiation and elongation. Mol. Cell 43, 263\u2013274 (2011).","journal-title":"Mol. Cell"},{"key":"1517_CR86","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1242\/jcs.02718","volume":"118","author":"RP Fisher","year":"2005","unstructured":"Fisher, R. P. Secrets of a double agent: CDK7 in cell-cycle control and transcription. J. Cell Sci. 118, 5171\u20135180 (2005).","journal-title":"J. Cell Sci."},{"key":"1517_CR87","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nsmb1028","volume":"13","author":"S Larochelle","year":"2006","unstructured":"Larochelle, S. et al. Dichotomous but stringent substrate selection by the dual-function CDK7 complex revealed by chemical genetics. Nat. Struct. Mol. Biol. 13, 55\u201362 (2006).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1517_CR88","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1101\/gad.341545.120","volume":"34","author":"JK Rimel","year":"2020","unstructured":"Rimel, J. K. et al. Selective inhibition of CDK7 reveals high-confidence targets and new models for TFIIH function in transcription. Genes Dev. 34, 1452\u20131473 (2020).","journal-title":"Genes Dev."},{"key":"1517_CR89","doi-asserted-by":"publisher","first-page":"gkaf1343","DOI":"10.1093\/nar\/gkaf1343","volume":"53","author":"M Rajecky","year":"2025","unstructured":"Rajecky, M. et al. CDK7\u2013CDK11 axis in spliceosome regulation and pre-mRNA splicing. Nucleic Acids Res. 53, gkaf1343 (2025).","journal-title":"Nucleic Acids Res."},{"key":"1517_CR90","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1126\/science.adw0053","volume":"390","author":"VI Cushing","year":"2025","unstructured":"Cushing, V. I. et al. Structural basis of T-loop-independent recognition and activation of CDKs by the CDK-activating kinase. Science 390, 911\u2013917 (2025). A structural approach revealed how CDK7 can expand its substrate repertoire to phosphorylate the activation loops of other CDKs independently of T-loop sequence.","journal-title":"Science"},{"key":"1517_CR91","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1128\/MCB.21.1.88-99.2001","volume":"21","author":"S Garrett","year":"2001","unstructured":"Garrett, S. et al. Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop. Mol. Cell Biol. 21, 88\u201399 (2001).","journal-title":"Mol. Cell Biol."},{"key":"1517_CR92","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.molcel.2008.10.022","volume":"32","author":"KA Merrick","year":"2008","unstructured":"Merrick, K. A. et al. Distinct activation pathways confer cyclin-binding specificity on CDK1 and CDK2 in human cells. Mol. Cell 32, 662\u2013672 (2008).","journal-title":"Mol. Cell"},{"key":"1517_CR93","doi-asserted-by":"publisher","first-page":"6208","DOI":"10.1158\/0008-5472.CAN-09-0301","volume":"69","author":"S Ali","year":"2009","unstructured":"Ali, S. et al. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res. 69, 6208\u20136215 (2009).","journal-title":"Cancer Res."},{"key":"1517_CR94","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.chembiol.2019.02.012","volume":"26","author":"CM Olson","year":"2019","unstructured":"Olson, C. M. et al. Development of a selective CDK7 covalent inhibitor reveals predominant cell-cycle phenotype. Cell Chem. Biol. 26, 792\u2013803.e710 (2019).","journal-title":"Cell Chem. Biol."},{"key":"1517_CR95","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1016\/j.molcel.2023.10.017","volume":"83","author":"GA Wilson","year":"2023","unstructured":"Wilson, G. A. et al. Active growth signaling promotes senescence and cancer cell sensitivity to CDK7 inhibition. Mol. Cell 83, 4078\u20134092.e4076 (2023).","journal-title":"Mol. Cell"},{"key":"1517_CR96","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41586-018-0440-4","volume":"560","author":"SM Vos","year":"2018","unstructured":"Vos, S. M. et al. Structure of activated transcription complex Pol II\u2013DSIF\u2013PAF\u2013SPT6. Nature 560, 607\u2013612 (2018).\u00a0This article presents a structural and biochemical analysis of the elongating RNA polymerase II (RNAPII) complex, revealing elongation control mechanisms and a collection of critical transcription cyclin-dependent kinase (tCDK)-dependent phosphorylation sites.","journal-title":"Nature"},{"key":"1517_CR97","doi-asserted-by":"publisher","first-page":"e00602","DOI":"10.1128\/MCB.00602-18","volume":"39","author":"Y Chun","year":"2019","unstructured":"Chun, Y. et al. Selective kinase inhibition shows that Bur1 (CDK9) phosphorylates the Rpb1 linker in vivo. Mol. Cell Biol. 39, e00602\u2013e00618 (2019).","journal-title":"Mol. Cell Biol."},{"key":"1517_CR98","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/j.molcel.2025.03.021","volume":"85","author":"R Sun","year":"2025","unstructured":"Sun, R. & Fisher, R. P. Tripartite phosphorylation of SPT5 by CDK9 times pause release and tunes elongation rate of RNA polymerase II. Mol. Cell 85, 1743\u20131759 (2025).","journal-title":"Mol. Cell"},{"key":"1517_CR99","doi-asserted-by":"publisher","first-page":"168746","DOI":"10.1016\/j.jmb.2024.168746","volume":"437","author":"R Sun","year":"2025","unstructured":"Sun, R. & Fisher, R. P. The CDK9\u2013SPT5 axis in control of transcription elongation by RNAPII. J. Mol. Biol. 437, 168746 (2025).","journal-title":"J. Mol. Biol."},{"key":"1517_CR100","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0092-8674(00)80713-8","volume":"97","author":"Y Yamaguchi","year":"1999","unstructured":"Yamaguchi, Y. et al. NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell 97, 41\u201351 (1999).","journal-title":"Cell"},{"key":"1517_CR101","doi-asserted-by":"publisher","first-page":"4413\u20134424.e5","DOI":"10.1016\/j.molcel.2021.08.006","volume":"81","author":"Y Aoi","year":"2021","unstructured":"Aoi, Y. et al. SPT5 stabilization of promoter-proximal RNA polymerase II. Mol. Cell 81, 4413\u20134424.e5 (2021).","journal-title":"Mol. Cell"},{"key":"1517_CR102","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1016\/j.molcel.2022.09.001","volume":"82","author":"N Fong","year":"2022","unstructured":"Fong, N., Sheridan, R. M., Ramachandran, S. & Bentley, D. L. The pausing zone and control of RNA polymerase II elongation by Spt5: implications for the pause-release model. Mol. Cell 82, 3632\u20133645 (2022).","journal-title":"Mol. Cell"},{"key":"1517_CR103","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1016\/j.molcel.2021.08.029","volume":"81","author":"S Hu","year":"2021","unstructured":"Hu, S. et al. SPT5 stabilizes RNA polymerase II, orchestrates transcription cycles, and maintains the enhancer landscape. Mol. Cell 81, 4425\u20134439 e4426 (2021).","journal-title":"Mol. Cell"},{"key":"1517_CR104","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.molcel.2015.09.026","volume":"60","author":"N Fong","year":"2015","unstructured":"Fong, N. et al. Effects of transcription elongation rate and Xrn2 exonuclease activity on RNA polymerase II termination suggest widespread kinetic competition. Mol. Cell 60, 256\u2013267 (2015).","journal-title":"Mol. Cell"},{"key":"1517_CR105","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nsmb.3000","volume":"22","author":"C Laitem","year":"2015","unstructured":"Laitem, C. et al. CDK9 inhibitors define elongation checkpoints at both ends of RNA polymerase II-transcribed genes. Nat. Struct. Mol. Biol. 22, 396\u2013403 (2015).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1517_CR106","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s12276-020-0442-9","volume":"52","author":"SH Choi","year":"2020","unstructured":"Choi, S. H., Kim, S. & Jones, K. A. Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation. Exp. Mol. Med. 52, 762\u2013771 (2020).","journal-title":"Exp. Mol. Med."},{"key":"1517_CR107","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-018-0758-y","volume":"564","author":"SJ Dubbury","year":"2018","unstructured":"Dubbury, S. J., Boutz, P. L. & Sharp, P. A. CDK12 regulates DNA repair genes by suppressing intronic polyadenylation. Nature 564, 141\u2013145 (2018).","journal-title":"Nature"},{"key":"1517_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09703-y","volume":"10","author":"M Krajewska","year":"2019","unstructured":"Krajewska, M. et al. CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nat. Commun. 10, 1757 (2019). Dubbury et al. and Krajewska et al. (refs. 107 and 108) revealed the mechanism by which CDK12 mutations recapitulate the BRCA mutated phenotype in cancer cells: premature termination of DNA damage response genes.","journal-title":"Nat. Commun."},{"key":"1517_CR109","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1101\/gad.1968210","volume":"24","author":"B Bartkowiak","year":"2010","unstructured":"Bartkowiak, B. et al. CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes Dev. 24, 2303\u20132316 (2010). This study identified CDK12 as the missing metazoan orthologue of yeast Ctk1 and a critical player in RNAPII elongation control.","journal-title":"Genes Dev."},{"key":"1517_CR110","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1101\/gad.231274.113","volume":"28","author":"L Davidson","year":"2014","unstructured":"Davidson, L., Muniz, L. & West, S. 3\u2019 end formation of pre-mRNA and phosphorylation of Ser2 on the RNA polymerase II CTD are reciprocally coupled in human cells. Genes Dev. 28, 342\u2013356 (2014).","journal-title":"Genes Dev."},{"key":"1517_CR111","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.molcel.2017.04.016","volume":"66","author":"N Fong","year":"2017","unstructured":"Fong, N., Saldi, T., Sheridan, R. M., Cortazar, M. A. & Bentley, D. L. RNA Pol II dynamics modulate co-transcriptional chromatin modification, CTD phosphorylation, and transcriptional direction. Mol. Cell 66, 546\u2013557.e543 (2017).","journal-title":"Mol. Cell"},{"key":"1517_CR112","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1101\/gr.8.9.929","volume":"8","author":"R Gururajan","year":"1998","unstructured":"Gururajan, R. et al. Duplication of a genomic region containing the Cdc2L1\u20132 and MMP21\u201322 genes on human chromosome 1p36.3 and their linkage to D1Z2. Genome Res. 8, 929\u2013939 (1998).","journal-title":"Genome Res."},{"key":"1517_CR113","doi-asserted-by":"publisher","first-page":"8623","DOI":"10.1074\/jbc.M210057200","volume":"278","author":"D Hu","year":"2003","unstructured":"Hu, D., Mayeda, A., Trembley, J. H., Lahti, J. M. & Kidd, V. J. CDK11 complexes promote pre-mRNA splicing. J. Biol. Chem. 278, 8623\u20138629 (2003).","journal-title":"J. Biol. Chem."},{"key":"1517_CR114","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/s41586-022-05204-z","volume":"609","author":"M Hluchy","year":"2022","unstructured":"Hluchy, M. et al. CDK11 regulates pre-mRNA splicing by phosphorylation of SF3B1. Nature 609, 829\u2013834 (2022). This study showed that CDK11, which had long been implicated in regulation of splicing, phosphorylates the conserved spliceosome component SF3B1.","journal-title":"Nature"},{"key":"1517_CR115","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1038\/s41467-026-71119-2","volume":"17","author":"P Gajduskova","year":"2026","unstructured":"Gajduskova, P. et al. Phosphorylation of SF3B1 by CDK11 orchestrates spliceosome activation via SNIP1-dependent RES complex recruitment.\u00a0Nat. Commun. 17, 4577 (2026).","journal-title":"Nat. Commun."},{"key":"1517_CR116","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41594-020-0406-8","volume":"27","author":"P Gajduskova","year":"2020","unstructured":"Gajduskova, P. et al. CDK11 is required fro transcription of replication-dependent histone genes. Nat. Struct. Mol. Biol. 27, 500\u2013510 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1517_CR117","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ajhg.2017.08.003","volume":"101","author":"C Windpassinger","year":"2017","unstructured":"Windpassinger, C. et al. CDK10 mutations in humans and mice cause severe growth retardation, spine malformations, and developmental delays. Am. J. Hum. Genet. 101, 391\u2013403 (2017).","journal-title":"Am. J. Hum. Genet."},{"key":"1517_CR118","doi-asserted-by":"publisher","first-page":"655479","DOI":"10.3389\/fonc.2021.655479","volume":"11","author":"ZA Bazzi","year":"2021","unstructured":"Bazzi, Z. A. & Tai, I. T. CDK10 in Gastrointestinal cancers: dual roles as a tumor suppressor and oncogene. Front. Oncol. 11, 655479 (2021).","journal-title":"Front. Oncol."},{"key":"1517_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74580-1","volume":"10","author":"A Mathioudaki","year":"2020","unstructured":"Mathioudaki, A. et al. Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort. Sci. Rep. 10, 19304 (2020).","journal-title":"Sci. Rep."},{"key":"1517_CR120","doi-asserted-by":"publisher","first-page":"27927","DOI":"10.1074\/jbc.M112.420265","volume":"288","author":"CW Yeh","year":"2013","unstructured":"Yeh, C. W., Kao, S. H., Cheng, Y. C. & Hsu, L. S. Knockdown of cyclin-dependent kinase 10 (cdk10) gene impairs neural progenitor survival via modulation of raf1a gene expression. J. Biol. Chem. 288, 27927\u201327939 (2013).","journal-title":"J. Biol. Chem."},{"key":"1517_CR121","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1172\/JCI45967","volume":"121","author":"H Feng","year":"2011","unstructured":"Feng, H. et al. Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives beta-catenin\/T cell factor-dependent hepatocarcinogenesis. J. Clin. Invest. 121, 3159\u20133175 (2011).","journal-title":"J. Clin. Invest."},{"key":"1517_CR122","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/embor.2013.80","volume":"14","author":"Y Yang","year":"2013","unstructured":"Yang, Y., Roine, N. & Makela, T. P. CCRK depletion inhibits glioblastoma cell proliferation in a cilium-dependent manner. EMBO Rep. 14, 741\u2013747 (2013).","journal-title":"EMBO Rep."},{"key":"1517_CR123","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","volume":"155","author":"D Hnisz","year":"2013","unstructured":"Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934\u2013947 (2013).","journal-title":"Cell"},{"key":"1517_CR124","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Loven","year":"2013","unstructured":"Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320\u2013334 (2013).","journal-title":"Cell"},{"key":"1517_CR125","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.molcel.2005.06.029","volume":"19","author":"Z Yang","year":"2005","unstructured":"Yang, Z. et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell 19, 535\u2013545 (2005).","journal-title":"Mol. Cell"},{"key":"1517_CR126","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.molcel.2005.06.027","volume":"19","author":"MK Jang","year":"2005","unstructured":"Jang, M. K. et al. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 19, 523\u2013534 (2005).","journal-title":"Mol. Cell"},{"key":"1517_CR127","doi-asserted-by":"publisher","first-page":"107884","DOI":"10.1016\/j.celrep.2020.107884","volume":"32","author":"W Shan","year":"2020","unstructured":"Shan, W. et al. Systematic characterization of recurrent genomic alterations in cyclin-dependent kinases reveals potential therapeutic strategies for cancer treatment. Cell Rep. 32, 107884 (2020).","journal-title":"Cell Rep."},{"key":"1517_CR128","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd.2018.21","volume":"17","author":"FM Ferguson","year":"2018","unstructured":"Ferguson, F. M. & Gray, N. S. Kinase inhibitors: the road ahead. Nat. Rev. Drug Discov. 17, 353\u2013377 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1517_CR129","doi-asserted-by":"publisher","first-page":"113925","DOI":"10.1016\/j.isci.2025.113925","volume":"28","author":"M Nukaya","year":"2025","unstructured":"Nukaya, M. et al. CDK7 is a novel therapeutic target in fibrolamellar carcinoma. iScience 28, 113925 (2025).","journal-title":"iScience"},{"key":"1517_CR130","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.cell.2014.10.024","volume":"159","author":"E Chipumuro","year":"2014","unstructured":"Chipumuro, E. et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell 159, 1126\u20131139 (2014).","journal-title":"Cell"},{"key":"1517_CR131","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.ccell.2014.10.019","volume":"26","author":"CL Christensen","year":"2014","unstructured":"Christensen, C. L. et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell 26, 909\u2013922 (2014).","journal-title":"Cancer Cell"},{"key":"1517_CR132","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.cell.2015.08.063","volume":"163","author":"Y Wang","year":"2015","unstructured":"Wang, Y. et al. CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell 163, 174\u2013186 (2015).","journal-title":"Cell"},{"key":"1517_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40061-y","volume":"14","author":"RC Coombes","year":"2023","unstructured":"Coombes, R. C. et al. Dose escalation and expansion cohorts in patients with advanced breast cancer in a phase I study of the CDK7-inhibitor samuraciclib. Nat. Commun. 14, 4444 (2023).","journal-title":"Nat. Commun."},{"key":"1517_CR134","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature07310","volume":"455","author":"EJ Morris","year":"2008","unstructured":"Morris, E. J. et al. E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature 455, 552\u2013556 (2008).","journal-title":"Nature"},{"key":"1517_CR135","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.immuni.2012.10.017","volume":"38","author":"J Bancerek","year":"2013","unstructured":"Bancerek, J. et al. CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response. Immunity 38, 250\u2013262 (2013).","journal-title":"Immunity"},{"key":"1517_CR136","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.cell.2010.03.030","volume":"141","author":"PB Rahl","year":"2010","unstructured":"Rahl, P. B. et al. c-Myc regulates transcriptional pause release. Cell 141, 432\u2013445 (2010).","journal-title":"Cell"},{"key":"1517_CR137","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.molcel.2019.02.031","volume":"74","author":"A Baluapuri","year":"2019","unstructured":"Baluapuri, A. et al. MYC recruits SPT5 to RNA polymerase II to promote processive transcription elongation. Mol. Cell 74, 674\u2013687 (2019).","journal-title":"Mol. Cell"},{"key":"1517_CR138","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41580-020-0215-2","volume":"21","author":"A Baluapuri","year":"2020","unstructured":"Baluapuri, A., Wolf, E. & Eilers, M. Target gene-independent functions of MYC oncoproteins. Nat. Rev. Mol. Cell Biol. 21, 255\u2013267 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1517_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5846","volume":"5","author":"N Stransky","year":"2014","unstructured":"Stransky, N., Cerami, E., Schalm, S., Kim, J. L. & Lengauer, C. The landscape of kinase fusions in cancer. Nat. Commun. 5, 4846 (2014).","journal-title":"Nat. Commun."},{"key":"1517_CR140","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature10509","volume":"478","author":"MA Dawson","year":"2011","unstructured":"Dawson, M. A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529\u2013533 (2011).","journal-title":"Nature"},{"key":"1517_CR141","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","volume":"168","author":"JE Bradner","year":"2017","unstructured":"Bradner, J. E., Hnisz, D. & Young, R. A. Transcriptional addiction in cancer. Cell 168, 629\u2013643 (2017).","journal-title":"Cell"},{"key":"1517_CR142","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1002\/cbic.200900303","volume":"10","author":"A Ali","year":"2009","unstructured":"Ali, A. et al. Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication. ChemBioChem 10, 2072\u20132080 (2009).","journal-title":"ChemBioChem"},{"key":"1517_CR143","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nchembio.2538","volume":"14","author":"CM Olson","year":"2018","unstructured":"Olson, C. M. et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat. Chem. Biol. 14, 163\u2013170 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"1517_CR144","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.06535","volume":"4","author":"H Lu","year":"2015","unstructured":"Lu, H. et al. Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism. eLife 4, e06535 (2015).","journal-title":"eLife"},{"key":"1517_CR145","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1093\/nar\/gkv101","volume":"43","author":"KM Ekumi","year":"2015","unstructured":"Ekumi, K. M. et al. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the CDK12\/CycK complex. Nucleic Acids Res. 43, 2575\u20132589 (2015).","journal-title":"Nucleic Acids Res."},{"key":"1517_CR146","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3389\/fonc.2019.00493","volume":"9","author":"NV Bogdanova","year":"2019","unstructured":"Bogdanova, N. V. et al. A splice site variant of CDK12 and breast cancer in three Eurasian populations. Front. Oncol. 9, 493 (2019).","journal-title":"Front. Oncol."},{"key":"1517_CR147","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ccell.2019.09.004","volume":"36","author":"V Quereda","year":"2019","unstructured":"Quereda, V. et al. Therapeutic targeting of CDK12\/CDK13 in triple-negative breast cancer. Cancer Cell 36, 545\u2013558.e547 (2019).","journal-title":"Cancer Cell"},{"key":"1517_CR148","doi-asserted-by":"publisher","first-page":"6698","DOI":"10.1093\/nar\/gkx187","volume":"45","author":"JF Tien","year":"2017","unstructured":"Tien, J. F. et al. CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion. Nucleic Acids Res. 45, 6698\u20136716 (2017).","journal-title":"Nucleic Acids Res."},{"key":"1517_CR149","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","volume":"174","author":"DA Quigley","year":"2018","unstructured":"Quigley, D. A. et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 174, 758\u2013769.e759 (2018).","journal-title":"Cell"},{"key":"1517_CR150","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cell.2018.05.036","volume":"174","author":"SR Viswanathan","year":"2018","unstructured":"Viswanathan, S. R. et al. Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing. Cell 174, 433\u2013447.e419 (2018).","journal-title":"Cell"},{"key":"1517_CR151","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","volume":"173","author":"YM Wu","year":"2018","unstructured":"Wu, Y. M. et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell 173, 1770\u20131782.e1714 (2018).","journal-title":"Cell"},{"key":"1517_CR152","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"1517_CR153","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","volume":"16","author":"CJ Lord","year":"2016","unstructured":"Lord, C. J. & Ashworth, A. BRCAness revisited. Nat. Rev. Cancer 16, 110\u2013120 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"1517_CR154","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1101\/gad.16962311","volume":"25","author":"D Blazek","year":"2011","unstructured":"Blazek, D. et al. The cyclin K\/CDK12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 25, 2158\u20132172 (2011).","journal-title":"Genes Dev."},{"key":"1517_CR155","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","volume":"17","author":"SF Johnson","year":"2016","unstructured":"Johnson, S. F. et al. CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer. Cell Rep. 17, 2367\u20132381 (2016).","journal-title":"Cell Rep."},{"key":"1517_CR156","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1159\/000491656","volume":"47","author":"X Dong","year":"2018","unstructured":"Dong, X. et al. CDK13 RNA over-editing mediated by ADAR1 associates with poor prognosis of hepatocellular carcinoma patients. Cell Physiol. Biochem. 47, 2602\u20132612 (2018).","journal-title":"Cell Physiol. Biochem."},{"key":"1517_CR157","doi-asserted-by":"publisher","first-page":"eabn7625","DOI":"10.1126\/science.abn7625","volume":"380","author":"ML Insco","year":"2023","unstructured":"Insco, M. L. et al. Oncogenic CDK13 mutations impede nuclear RNA surveillance. Science 380, eabn7625 (2023). This study revealed a tumour-suppressor function of CDK13; CDK13 mutation in a zebrafish melanoma model resulted in more aggressive malignancy.","journal-title":"Science"},{"key":"1517_CR158","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.jmoldx.2021.08.010","volume":"23","author":"A Elliott","year":"2021","unstructured":"Elliott, A. et al. Predicted immunogenicity of CDK12 biallelic loss-of-function tumors varies across cancer types. J. Mol. Diag. 23, 1761\u20131773 (2021).","journal-title":"J. Mol. Diag."},{"key":"1517_CR159","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s43018-025-01100-3","volume":"7","author":"G Xu","year":"2026","unstructured":"Xu, G. et al. CDK10 suppresses nucleic acid sensors-mediated antitumor immunity. Nat. Cancer 7, 283\u2013303 (2026).","journal-title":"Nat. Cancer"},{"key":"1517_CR160","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s43018-025-01101-2","volume":"7","author":"NS Firmino","year":"2026","unstructured":"Firmino, N. S. & West, N. R. CDK10 inhibits innate sensing to constrain antitumor immunity. Nat. Cancer 7, 254\u2013256 (2026).","journal-title":"Nat. Cancer"},{"key":"1517_CR161","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar, U., Witkiewicz, A. K., Turner, N. C. & Knudsen, E. S. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat. Rev. Drug Discov. 14, 130\u2013146 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1517_CR162","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41573-026-01431-5","volume":"25","author":"ES Knudsen","year":"2026","unstructured":"Knudsen, E. S., Witkiewicz, A. K. & Kabraji, S. The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond. Nat. Rev. Drug Discov. 25, 516\u2013533 (2026).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1517_CR163","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","volume":"27","author":"B Xu","year":"2021","unstructured":"Xu, B. et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat. Med. 27, 1904\u20131909 (2021).","journal-title":"Nat. Med."},{"key":"1517_CR164","doi-asserted-by":"publisher","first-page":"129769","DOI":"10.1016\/j.bmcl.2024.129769","volume":"107","author":"Z Xu","year":"2024","unstructured":"Xu, Z. et al. Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor. Bioorg. Med. Chem. Lett. 107, 129769 (2024).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"1517_CR165","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1535-7163.MCT-16-0847","volume":"17","author":"H Patel","year":"2018","unstructured":"Patel, H. et al. ICEC0942, an orally bioavailable selective inhibitor of CDK7 for cancer treatment. Mol. Cancer Ther. 17, 1156\u20131166 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"1517_CR166","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/s41416-023-02252-8","volume":"128","author":"TA Constantin","year":"2023","unstructured":"Constantin, T. A. et al. The CDK7 inhibitor CT7001 (samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. Br. J. Cancer 128, 2326\u20132337 (2023).","journal-title":"Br. J. Cancer"},{"key":"1517_CR167","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1021\/acs.jmedchem.1c01171","volume":"65","author":"JJ Marineau","year":"2022","unstructured":"Marineau, J. J. et al. Discovery of SY-5609: a selective, noncovalent inhibitor of CDK7. J. Med. Chem. 65, 1458\u20131480 (2022).","journal-title":"J. Med. Chem."},{"key":"1517_CR168","doi-asserted-by":"publisher","first-page":"eadr9660","DOI":"10.1126\/sciadv.adr9660","volume":"11","author":"T Jones","year":"2025","unstructured":"Jones, T. et al. TFIIH kinase CDK7 drives cell proliferation through a common core transcription factor network. Sci. Adv. 11, eadr9660 (2025).","journal-title":"Sci. Adv."},{"key":"1517_CR169","doi-asserted-by":"publisher","first-page":"8952","DOI":"10.1002\/anie.200904778","volume":"48","author":"VJ Cee","year":"2009","unstructured":"Cee, V. J., Chen, D. Y., Lee, M. R. & Nicolaou, K. C. Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11. Angew. Chem. Int. Ed.\u00a048, 8952\u20138957 (2009).","journal-title":"Angew. Chem. Int. Ed."},{"key":"1517_CR170","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nchembio.1952","volume":"11","author":"T Dale","year":"2015","unstructured":"Dale, T. et al. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Nat. Chem. Biol. 11, 973\u2013980 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"1517_CR171","doi-asserted-by":"publisher","first-page":"102247","DOI":"10.1016\/j.jbc.2022.102247","volume":"298","author":"C Arter","year":"2022","unstructured":"Arter, C., Trask, L., Ward, S., Yeoh, S. & Bayliss, R. Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors. J. Biol. Chem. 298, 102247 (2022).","journal-title":"J. Biol. Chem."},{"key":"1517_CR172","doi-asserted-by":"publisher","first-page":"9337","DOI":"10.1021\/acs.jmedchem.6b00597","volume":"59","author":"P Czodrowski","year":"2016","unstructured":"Czodrowski, P. et al. Structure-based optimization of potent, selective, and orally bioavailable CDK8 inhibitors discovered by high-throughput screening. J. Med. Chem. 59, 9337\u20139349 (2016).","journal-title":"J. Med. Chem."},{"key":"1517_CR173","doi-asserted-by":"publisher","first-page":"28345","DOI":"10.1074\/jbc.C000446200","volume":"275","author":"SH Chao","year":"2000","unstructured":"Chao, S. H. et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 275, 28345\u201328348 (2000).","journal-title":"J. Biol. Chem."},{"key":"1517_CR174","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1038\/emboj.2008.121","volume":"27","author":"S Baumli","year":"2008","unstructured":"Baumli, S. et al. The structure of P-TEFb (CDK9\/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J. 27, 1907\u20131918 (2008).","journal-title":"EMBO J."},{"key":"1517_CR175","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.chembiol.2010.07.012","volume":"17","author":"S Baumli","year":"2010","unstructured":"Baumli, S., Endicott, J. A. & Johnson, L. N. Halogen bonds form the basis for selective P-TEFb inhibition by DRB. Chem. Biol. 17, 931\u2013936 (2010).","journal-title":"Chem. Biol."},{"key":"1517_CR176","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-4-47","volume":"4","author":"S Biglione","year":"2007","unstructured":"Biglione, S. et al. Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology 4, 47 (2007).","journal-title":"Retrovirology"},{"key":"1517_CR177","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0092-8674(00)80939-3","volume":"92","author":"P Wei","year":"1998","unstructured":"Wei, P., Garber, M. E., Fang, S. M., Fischer, W. H. & Jones, K. A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92, 451\u2013462 (1998).","journal-title":"Cell"},{"key":"1517_CR178","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.molcel.2006.06.014","volume":"23","author":"BM Peterlin","year":"2006","unstructured":"Peterlin, B. M. & Price, D. H. Controlling the elongation phase of transcription with P-TEFb. Mol. Cell 23, 297\u2013305 (2006).","journal-title":"Mol. Cell"},{"key":"1517_CR179","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.chom.2011.11.002","volume":"10","author":"M Ott","year":"2011","unstructured":"Ott, M., Geyer, M. & Zhou, Q. The control of HIV transcription: keeping RNA polymerase II on track. Cell Host Microbe 10, 426\u2013435 (2011).","journal-title":"Cell Host Microbe"},{"key":"1517_CR180","doi-asserted-by":"publisher","first-page":"31793","DOI":"10.1074\/jbc.M102306200","volume":"276","author":"SH Chao","year":"2001","unstructured":"Chao, S. H. & Price, D. H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem. 276, 31793\u201331799 (2001).","journal-title":"J. Biol. Chem."},{"key":"1517_CR181","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.4161\/cc.3.12.1278","volume":"3","author":"MV Blagosklonny","year":"2004","unstructured":"Blagosklonny, M. V. Flavopiridol, an inhibitor of transcription: implications, problems and solutions. Cell Cycle 3, 1537\u20131542 (2004).","journal-title":"Cell Cycle"},{"key":"1517_CR182","unstructured":"Barsanti, P. A. et al. Pyridine and pyrzaine derivatives as protein kinase modulators. Google patent GE-P20146101-B, https:\/\/patents.google.com\/patent\/GEP20146101B (2011)."},{"key":"1517_CR183","doi-asserted-by":"publisher","first-page":"2219470","DOI":"10.1080\/15384047.2023.2219470","volume":"24","author":"L Xiao","year":"2023","unstructured":"Xiao, L., Liu, Y., Chen, H. & Shen, L. Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments. Cancer Biol. Ther. 24, 2219470 (2023).","journal-title":"Cancer Biol. Ther."},{"key":"1517_CR184","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1021\/jm0305568","volume":"47","author":"RN Misra","year":"2004","unstructured":"Misra, R. N. et al. N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J. Med. Chem. 47, 1719\u20131728 (2004).","journal-title":"J. Med. Chem."},{"key":"1517_CR185","doi-asserted-by":"publisher","first-page":"11651","DOI":"10.1021\/acs.jmedchem.1c01000","volume":"64","author":"U Lucking","year":"2021","unstructured":"Lucking, U. et al. Changing for the better: discovery of the highly potent and selective CDK9 Inhibitor VIP152 suitable for once weekly intravenous dosing for the treatment of cancer. J. Med. Chem. 64, 11651\u201311674 (2021).","journal-title":"J. Med. Chem."},{"key":"1517_CR186","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41375-022-01758-z","volume":"37","author":"S Sher","year":"2023","unstructured":"Sher, S. et al. VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia. Leukemia 37, 326\u2013338 (2023).","journal-title":"Leukemia"},{"key":"1517_CR187","doi-asserted-by":"publisher","first-page":"15189","DOI":"10.1021\/acs.jmedchem.1c01249","volume":"64","author":"B Barlaam","year":"2021","unstructured":"Barlaam, B. et al. Discovery of a series of 7-azaindoles as potent and highly selective CDK9 inhibitors for transient target engagement. J. Med. Chem. 64, 15189\u201315213 (2021).","journal-title":"J. Med. Chem."},{"key":"1517_CR188","doi-asserted-by":"publisher","first-page":"15564","DOI":"10.1021\/acs.jmedchem.0c01754","volume":"63","author":"B Barlaam","year":"2020","unstructured":"Barlaam, B. et al. Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables short duration of target engagement for the treatment of hematological malignancies. J. Med. Chem. 63, 15564\u201315590 (2020).","journal-title":"J. Med. Chem."},{"key":"1517_CR189","doi-asserted-by":"publisher","first-page":"eaaw8412","DOI":"10.1126\/scitranslmed.aaw8412","volume":"11","author":"A Lin","year":"2019","unstructured":"Lin, A. et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci. Transl. Med. 11, eaaw8412 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1517_CR190","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.str.2022.10.003","volume":"30","author":"S Kelso","year":"2022","unstructured":"Kelso, S., O\u2019Brien, S., Kurinov, I., Angers, S. & Sicheri, F. Crystal structure of the CDK11 kinase domain bound to the small-molecule inhibitor OTS964. Structure 30, 1615\u20131625 e1614 (2022).","journal-title":"Structure"},{"key":"1517_CR191","doi-asserted-by":"publisher","first-page":"114433","DOI":"10.1016\/j.ejmech.2022.114433","volume":"238","author":"Z Li","year":"2022","unstructured":"Li, Z. et al. Synthesis and structure\u2013activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold. Eur. J. Med. Chem. 238, 114433 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"1517_CR192","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.tcb.2024.08.004","volume":"35","author":"M Hluchy","year":"2025","unstructured":"Hluchy, M. & Blazek, D. CDK11, a splicing-associated kinase regulating gene expression. Trends Cell Biol. 35, 702\u2013716 (2025).","journal-title":"Trends Cell Biol."},{"key":"1517_CR193","doi-asserted-by":"publisher","unstructured":"Julian, L. et al. On-target toxicity limits the efficacy of CDK11 inhibition against cancers with 1p36 deletions. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.08.03.668359 (2025).","DOI":"10.1101\/2025.08.03.668359"},{"key":"1517_CR194","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1021\/ml100051d","volume":"1","author":"K Paruch","year":"2010","unstructured":"Paruch, K. et al. Discovery of dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases. ACS Med. Chem. Lett. 1, 204\u2013208 (2010).","journal-title":"ACS Med. Chem. Lett."},{"key":"1517_CR195","doi-asserted-by":"publisher","first-page":"7710","DOI":"10.1021\/acs.jmedchem.8b00683","volume":"61","author":"M Ito","year":"2018","unstructured":"Ito, M. et al. Discovery of 3-benzyl-1-(trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea derivatives as novel and selective cyclin-dependent kinase 12 (CDK12) inhibitors. J. Med. Chem. 61, 7710\u20137728 (2018).","journal-title":"J. Med. Chem."},{"key":"1517_CR196","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1073\/pnas.1313733111","volume":"111","author":"PA Schwartz","year":"2014","unstructured":"Schwartz, P. A. et al. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance. Proc. Natl Acad. Sci. USA 111, 173\u2013178 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1517_CR197","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4505","volume":"5","author":"CA B\u00f6sken","year":"2014","unstructured":"B\u00f6sken, C. A. et al. The structure and substrate specificity of human CDK12\/cyclin K. Nat. Commun. 5, 3505 (2014).","journal-title":"Nat. Commun."},{"key":"1517_CR198","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.celrep.2015.12.025","volume":"14","author":"AK Greifenberg","year":"2016","unstructured":"Greifenberg, A. K. et al. Structural and functional analysis of the CDK13\/cyclin K complex. Cell Rep. 14, 320\u2013331 (2016).","journal-title":"Cell Rep."},{"key":"1517_CR199","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-19-0119","volume":"79","author":"S Hu","year":"2019","unstructured":"Hu, S. et al. Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7. Cancer Res. 79, 3479\u20133491 (2019).","journal-title":"Cancer Res."},{"key":"1517_CR200","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.molcel.2007.02.003","volume":"25","author":"S Larochelle","year":"2007","unstructured":"Larochelle, S. et al. Requirements for CDK7 in the assembly of CDK1\/cyclin B and activation of CDK2 revealed by chemical genetics in human cells. Mol. Cell 25, 839\u2013850 (2007).","journal-title":"Mol. Cell"},{"key":"1517_CR201","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ccell.2019.11.003","volume":"37","author":"H Zhang","year":"2020","unstructured":"Zhang, H. et al. CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer. Cancer Cell 37, 37\u201354.e39 (2020).","journal-title":"Cancer Cell"},{"key":"1517_CR202","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/cancers14071690","volume":"14","author":"K Funke","year":"2022","unstructured":"Funke, K. et al. Transcriptional CDK inhibitors as potential treatment option for testicular germ cell tumors. Cancers 14, 1690 (2022).","journal-title":"Cancers"},{"key":"1517_CR203","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nchembio.2166","volume":"12","author":"T Zhang","year":"2016","unstructured":"Zhang, T. et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat. Chem. Biol. 12, 876\u2013884 (2016). This paper describes modification of the THZ1 scaffold to develop the first covalent inhibitors of CDK12 and CDK13.","journal-title":"Nat. Chem. Biol."},{"key":"1517_CR204","doi-asserted-by":"publisher","first-page":"113481","DOI":"10.1016\/j.ejmech.2021.113481","volume":"221","author":"B Jiang","year":"2021","unstructured":"Jiang, B. et al. Structure\u2013activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12\/13 covalent inhibitor with efficacy in Ewing sarcoma. Eur. J. Med. Chem. 221, 113481 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"1517_CR205","doi-asserted-by":"publisher","first-page":"6708","DOI":"10.1021\/acs.jmedchem.9b01929","volume":"63","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Discovery of MFH290: a potent and highly selective covalent inhibitor for cyclin-dependent kinase 12\/13. J. Med. Chem. 63, 6708\u20136726 (2020).","journal-title":"J. Med. Chem."},{"key":"1517_CR206","doi-asserted-by":"publisher","first-page":"6718","DOI":"10.1021\/acs.jmedchem.5c00127","volume":"68","author":"J Yang","year":"2025","unstructured":"Yang, J. et al. Discovery of YJZ5118: a potent and highly selective irreversible CDK12\/13 inhibitor with synergistic effects in combination with Akt inhibition. J. Med. Chem. 68, 6718\u20136734 (2025).","journal-title":"J. Med. Chem."},{"key":"1517_CR207","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M Bekes","year":"2022","unstructured":"Bekes, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181\u2013200 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1517_CR208","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","volume":"25","author":"JM Tsai","year":"2024","unstructured":"Tsai, J. M., Nowak, R. P., Ebert, B. L. & Fischer, E. S. Targeted protein degradation: from mechanisms to clinic. Nat. Rev. Mol. Cell Biol. 25, 740\u2013757 (2024).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1517_CR209","doi-asserted-by":"publisher","first-page":"7577","DOI":"10.1039\/C7CC03879H","volume":"53","author":"CM Robb","year":"2017","unstructured":"Robb, C. M. et al. Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chem. Commun. 53, 7577\u20137580 (2017).","journal-title":"Chem. Commun."},{"key":"1517_CR210","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41589-021-00765-y","volume":"17","author":"B Jiang","year":"2021","unstructured":"Jiang, B. et al. Discovery and resistance mechanism of a selective CDK12 degrader. Nat. Chem. Biol. 17, 675\u2013683 (2021).","journal-title":"Nat. Chem. Biol."},{"key":"1517_CR211","doi-asserted-by":"publisher","first-page":"114012","DOI":"10.1016\/j.ejmech.2021.114012","volume":"228","author":"T Niu","year":"2022","unstructured":"Niu, T. et al. Noncovalent CDK12\/13 dual inhibitors-based PROTACs degrade CDK12-cyclin K complex and induce synthetic lethality with PARP inhibitor. Eur. J. Med. Chem. 228, 114012 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"1517_CR212","doi-asserted-by":"publisher","first-page":"11066","DOI":"10.1021\/acs.jmedchem.2c00384","volume":"65","author":"J Yang","year":"2022","unstructured":"Yang, J. et al. Discovery of a highly potent and selective dual PROTAC Degrader of CDK12 and CDK13. J. Med. Chem. 65, 11066\u201311083 (2022).","journal-title":"J. Med. Chem."},{"key":"1517_CR213","doi-asserted-by":"publisher","first-page":"101752","DOI":"10.1016\/j.xcrm.2024.101752","volume":"5","author":"Y Chang","year":"2024","unstructured":"Chang, Y. et al. Development of an orally bioavailable CDK12\/13 degrader and induction of synthetic lethality with AKT pathway inhibition. Cell Rep. Med. 5, 101752 (2024).","journal-title":"Cell Rep. Med."},{"key":"1517_CR214","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1021\/acsmedchemlett.8b00011","volume":"9","author":"JM Hatcher","year":"2018","unstructured":"Hatcher, J. M. et al. Development of highly potent and selective steroidal inhibitors and degraders of CDK8. ACS Med. Chem. Lett. 9, 540\u2013545 (2018).","journal-title":"ACS Med. Chem. Lett."},{"key":"1517_CR215","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12656-x","volume":"10","author":"I Menzl","year":"2019","unstructured":"Menzl, I. et al. A kinase-independent role for CDK8 in BCR-ABL1+ leukemia. Nat. Commun. 10, 4741 (2019).","journal-title":"Nat. Commun."},{"key":"1517_CR216","doi-asserted-by":"publisher","first-page":"116613","DOI":"10.1016\/j.ejmech.2024.116613","volume":"276","author":"W Ji","year":"2024","unstructured":"Ji, W. et al. Discovery of bivalent small molecule degraders of cyclin-dependent kinase 7 (CDK7. Eur. J. Med. Chem. 276, 116613 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"1517_CR217","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-020-2374-x","volume":"585","author":"M Slabicki","year":"2020","unstructured":"Slabicki, M. et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature 585, 293\u2013297 (2020). This study reports the discovery of the prototypic molecular glue CR8, recruiting DDB1 to CDK12, yet degrading cyclin K.","journal-title":"Nature"},{"key":"1517_CR218","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41589-020-0594-x","volume":"16","author":"C Mayor-Ruiz","year":"2020","unstructured":"Mayor-Ruiz, C. et al. Rational discovery of molecular glue degraders via scalable chemical profiling. Nat. Chem. Biol. 16, 1199\u20131207 (2020). Together with Slabicki et al. (ref. 217), this study establishes the targeting of CDK12 by molecular glue degraders.","journal-title":"Nat. Chem. Biol."},{"key":"1517_CR219","doi-asserted-by":"publisher","first-page":"105501","DOI":"10.1016\/j.jbc.2023.105501","volume":"300","author":"M Schmitz","year":"2024","unstructured":"Schmitz, M. et al. The reversible inhibitor SR-4835 binds CDK12\/cyclin K in a noncanonical G-loop conformation. J. Biol. Chem. 300, 105501 (2024).","journal-title":"J. Biol. Chem."},{"key":"1517_CR220","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1039\/D4CB00190G","volume":"6","author":"P Ghosh","year":"2024","unstructured":"Ghosh, P. et al. Discovery and design of molecular glue enhancers of CDK12\u2013DDB1 interactions for targeted degradation of cyclin K. RSC Chem. Biol. 6, 36\u201355 (2024).","journal-title":"RSC Chem. Biol."},{"key":"1517_CR221","doi-asserted-by":"publisher","first-page":"109394","DOI":"10.1016\/j.celrep.2021.109394","volume":"36","author":"SM Dieter","year":"2021","unstructured":"Dieter, S. M. et al. Degradation of CCNK\/CDK12 is a druggable vulnerability of colorectal cancer. Cell Rep. 36, 109394 (2021).","journal-title":"Cell Rep."},{"key":"1517_CR222","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41420-023-01754-x","volume":"9","author":"T Houles","year":"2023","unstructured":"Houles, T. et al. The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma. Cell Death Discov. 9, 459 (2023).","journal-title":"Cell Death Discov."},{"key":"1517_CR223","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41589-023-01409-z","volume":"20","author":"Z Kozicka","year":"2024","unstructured":"Kozicka, Z. et al. Design principles for cyclin K molecular glue degraders. Nat. Chem. Biol. 20, 93\u2013102 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"1517_CR224","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50642-0","volume":"15","author":"Z Zhang","year":"2024","unstructured":"Zhang, Z. et al. Dual-site molecular glues for enhancing protein\u2013protein interactions of the CDK12\u2013DDB1 complex. Nat. Commun. 15, 6477 (2024).","journal-title":"Nat. Commun."},{"key":"1517_CR225","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1021\/acs.jmedchem.5c02086","volume":"69","author":"T Pandurangan","year":"2026","unstructured":"Pandurangan, T. et al. Structure\u2013activity and structure-degradation relationship studies of 2-amino-6-(benzimidazol-2-ylmethyl)-N9-heteroarylpurines as potent and selective CDK12\/13 inhibitors and cyclin K degraders. J. Med. Chem.\u00a069, 2287\u20132309 (2026).","journal-title":"J. Med. Chem."},{"key":"1517_CR226","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1021\/cb100410m","volume":"6","author":"S Betzi","year":"2011","unstructured":"Betzi, S. et al. Discovery of a potential allosteric ligand binding site in CDK2. ACS Chem. Biol. 6, 492\u2013501 (2011).","journal-title":"ACS Chem. Biol."},{"key":"1517_CR227","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38732-x","volume":"14","author":"EB Faber","year":"2023","unstructured":"Faber, E. B. et al. Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding. Nat. Commun. 14, 3213 (2023).","journal-title":"Nat. Commun."},{"key":"1517_CR228","doi-asserted-by":"publisher","first-page":"eadl5361","DOI":"10.1126\/science.adl5361","volume":"386","author":"RC Sarott","year":"2024","unstructured":"Sarott, R. C. et al. Relocalizing transcriptional kinases to activate apoptosis. Science 386, eadl5361 (2024). This study introduces a new concept by linking a binder of CDK9 with a ligand of BCL6 to enforce CDK9 proximity at BCL6 target genes and enhance transcriptional elongation.","journal-title":"Science"},{"key":"1517_CR229","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-023-06348-2","volume":"620","author":"S Gourisankar","year":"2023","unstructured":"Gourisankar, S. et al. Rewiring cancer drivers to activate apoptosis. Nature 620, 417\u2013425 (2023).","journal-title":"Nature"},{"key":"1517_CR230","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.cell.2007.01.021","volume":"128","author":"ZA Knight","year":"2007","unstructured":"Knight, Z. A. & Shokat, K. M. Chemical genetics: where genetics and pharmacology meet. Cell 128, 425\u2013430 (2007).","journal-title":"Cell"},{"key":"1517_CR231","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.29736","volume":"6","author":"S Gressel","year":"2017","unstructured":"Gressel, S. et al. CDK9-dependent RNA polymerase II pausing controls transcription initiation. eLife 6, e29736 (2017).","journal-title":"eLife"},{"key":"1517_CR232","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.bbagrm.2015.07.010","volume":"1849","author":"B Bartkowiak","year":"2015","unstructured":"Bartkowiak, B., Yan, C. & Greenleaf, A. L. Engineering an analog-sensitive CDK12 cell line using CRISPR\/Cas. Biochim. Biophys. Acta 1849, 1179\u20131187 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"1517_CR233","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.molcel.2009.06.036","volume":"35","author":"N Johnson","year":"2009","unstructured":"Johnson, N. et al. CDK1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. Mol. Cell 35, 327\u2013339 (2009).","journal-title":"Mol. Cell"},{"key":"1517_CR234","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm.2377","volume":"17","author":"N Johnson","year":"2011","unstructured":"Johnson, N. et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat. Med. 17, 875\u2013882 (2011).","journal-title":"Nat. Med."},{"key":"1517_CR235","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1517\/14728222.2010.525221","volume":"14","author":"N Johnson","year":"2010","unstructured":"Johnson, N. & Shapiro, G. I. Cyclin-dependent kinases (CDKs) and the DNA damage response: rationale for CDK inhibitor\u2013chemotherapy combinations as an anticancer strategy for solid tumors. Exp. Opin. Ther. Targets 14, 1199\u20131212 (2010).","journal-title":"Exp. Opin. Ther. Targets"},{"key":"1517_CR236","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrg.2017.47","volume":"18","author":"NJ O\u2019Neil","year":"2017","unstructured":"O\u2019Neil, N. J., Bailey, M. L. & Hieter, P. Synthetic lethality and cancer. Nat. Rev. Genet.\u00a018, 613\u2013623\u00a0(2017).","journal-title":"Nat. Rev. Genet."},{"key":"1517_CR237","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.celrep.2017.09.056","volume":"21","author":"S Kalan","year":"2017","unstructured":"Kalan, S. et al. Activation of the p53 transcriptional program sensitizes cancer cells to CDK7 inhibitors. Cell Rep. 21, 467\u2013481 (2017).","journal-title":"Cell Rep."},{"key":"1517_CR238","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1093\/nar\/gkad001","volume":"51","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. P-TEFb promotes cell survival upon p53 activation by suppressing intrinsic apoptosis pathway. Nucleic Acids Res. 51, 1687\u20131706 (2023).","journal-title":"Nucleic Acids Res."},{"key":"1517_CR239","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cell.2018.07.045","volume":"175","author":"W Minzel","year":"2018","unstructured":"Minzel, W. et al. Small molecules co-targeting CKI\u03b1 and the transcriptional kinases CDK7\/9 control AML in preclinical models. Cell 175, 171\u2013185.e125 (2018).","journal-title":"Cell"},{"key":"1517_CR240","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.cell.2018.09.051","volume":"175","author":"H Zhang","year":"2018","unstructured":"Zhang, H. et al. Targeting CDK9 reactivates epigenetically silenced genes in cancer. Cell 175, 1244\u20131258.e1226 (2018).","journal-title":"Cell"},{"key":"1517_CR241","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1158\/2159-8290.CD-20-1848","volume":"12","author":"Z Qiu","year":"2022","unstructured":"Qiu, Z. et al. Transcription elongation machinery is a druggable dependency and potentiates immunotherapy in glioblastoma stem cells. Cancer Discov. 12, 502\u2013521 (2022).","journal-title":"Cancer Discov."},{"key":"1517_CR242","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41388-024-02947-z","volume":"43","author":"AC Cannon","year":"2024","unstructured":"Cannon, A. C. et al. Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. Oncogene 43, 729\u2013743 (2024).","journal-title":"Oncogene"},{"key":"1517_CR243","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1101\/gad.348315.121","volume":"35","author":"G Cossa","year":"2021","unstructured":"Cossa, G., Parua, P. K., Eilers, M. & Fisher, R. P. Protein phosphatases in the RNAPII transcription cycle: erasers, sculptors, gatekeepers, and potential drug targets. Genes Dev. 35, 658\u2013676 (2021).","journal-title":"Genes Dev."},{"key":"1517_CR244","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.cell.2020.04.005","volume":"181","author":"J Westermarck","year":"2020","unstructured":"Westermarck, J. & Neel, B. G. Piecing together a broken tumor suppressor phosphatase for cancer therapy. Cell 181, 514\u2013517 (2020).","journal-title":"Cell"},{"key":"1517_CR245","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.cell.2020.03.038","volume":"181","author":"D Leonard","year":"2020","unstructured":"Leonard, D. et al. Selective PP2A enhancement through biased heterotrimer stabilization. Cell 181, 688\u2013701.e616 (2020).","journal-title":"Cell"},{"key":"1517_CR246","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nrc.2017.79","volume":"11","author":"Z Karoulia","year":"2017","unstructured":"Karoulia, Z., Gavathiotis, E. & Poulikakos, P. I. New perspectives for targeting RAF kinase in human cancer. Nat. Rev. Cancer 11, 676\u2013691 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"1517_CR247","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev-biochem-052610-095910","volume":"81","author":"Q Zhou","year":"2012","unstructured":"Zhou, Q., Li, T. & Price, D. H. RNA polymerase II elongation control. Ann. Rev. Biochem. 81, 119\u2013143 (2012).","journal-title":"Ann. Rev. Biochem."},{"key":"1517_CR248","doi-asserted-by":"publisher","first-page":"7577","DOI":"10.1093\/nar\/gku449","volume":"42","author":"F Itzen","year":"2014","unstructured":"Itzen, F., Greifenberg, A. K., Bosken, C. A. & Geyer, M. Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation. Nucleic Acids Res. 42, 7577\u20137590 (2014).","journal-title":"Nucleic Acids Res."},{"key":"1517_CR249","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/21541264.2018.1523668","volume":"10","author":"CW Bacon","year":"2019","unstructured":"Bacon, C. W. & D\u2019Orso, I. CDK9: a signaling hub for transcriptional control. Transcription 10, 57\u201375 (2019).","journal-title":"Transcription"},{"key":"1517_CR250","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1097-2765(00)80239-7","volume":"5","author":"S Cornelis","year":"2000","unstructured":"Cornelis, S. et al. Identification and characterization of a novel cell cycle-regulated internal ribosome entry site. Mol. Cell 5, 597\u2013605 (2000).","journal-title":"Mol. Cell"},{"key":"1517_CR251","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.cell.2018.09.027","volume":"175","author":"K Liang","year":"2018","unstructured":"Liang, K. et al. Targeting processive transcription elongation via SEC disruption for MYC-induced cancer therapy. Cell 175, 766\u2013779.e717 (2018).","journal-title":"Cell"},{"key":"1517_CR252","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/ph16040519","volume":"16","author":"M Klein","year":"2023","unstructured":"Klein, M. Targeting protein\u2013protein interactions to inhibit cyclin-dependent kinases. Pharmaceuticals 16, 519 (2023).","journal-title":"Pharmaceuticals"},{"key":"1517_CR253","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","volume":"620","author":"JL Watson","year":"2023","unstructured":"Watson, J. L. et al. De novo design of protein structure and function with RFdiffusion. Nature 620, 1089\u20131100 (2023).","journal-title":"Nature"},{"key":"1517_CR254","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41586-025-09429-6","volume":"646","author":"M Pacesa","year":"2025","unstructured":"Pacesa, M. et al. One-shot design of functional protein binders with BindCraft. Nature 646, 483\u2013492 (2025).","journal-title":"Nature"},{"key":"1517_CR255","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/nature11127","volume":"486","author":"AC Dar","year":"2012","unstructured":"Dar, A. C., Das, T. K., Shokat, K. M. & Cagan, R. L. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature 486, 80\u201384 (2012).","journal-title":"Nature"},{"key":"1517_CR256","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.chembiol.2017.11.007","volume":"25","author":"Y Gao","year":"2018","unstructured":"Gao, Y. et al. Overcoming resistance to the THZ series of covalent transcriptional CDK inhibitors. Cell Chem. Biol. 25, 135\u2013142.e135 (2018).","journal-title":"Cell Chem. Biol."},{"key":"1517_CR257","doi-asserted-by":"publisher","first-page":"5860","DOI":"10.1038\/s44318-025-00554-6","volume":"44","author":"CF Lai","year":"2025","unstructured":"Lai, C. F. et al. Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells. EMBO J. 44, 5860\u20135889 (2025).","journal-title":"EMBO J."},{"key":"1517_CR258","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1016\/j.apsb.2023.05.026","volume":"13","author":"C Hu","year":"2023","unstructured":"Hu, C. et al. Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy. Acta Pharm. Sin. B 13, 3694\u20133707 (2023).","journal-title":"Acta Pharm. Sin. B"},{"key":"1517_CR259","doi-asserted-by":"publisher","first-page":"8106","DOI":"10.1021\/acs.jmedchem.4c02548","volume":"68","author":"C Shi","year":"2025","unstructured":"Shi, C. et al. Discovery of a novel dihydroisoquinolinone derivative as a potent CDK9 inhibitor capable of overcoming L156F mutant for the treatment of hematologic malignancies. J. Med. Chem. 68, 8106\u20138123 (2025).","journal-title":"J. Med. Chem."},{"key":"1517_CR260","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1021\/cb200551p","volume":"7","author":"ME Burkard","year":"2012","unstructured":"Burkard, M. E., Santamaria, A. & Jallepalli, P. V. Enabling and disabling polo-like kinase 1 inhibition through chemical genetics. ACS Chem. Biol. 7, 978\u2013981 (2012).","journal-title":"ACS Chem. Biol."},{"key":"1517_CR261","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876\u2013880 (2001).","journal-title":"Science"},{"key":"1517_CR262","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1158\/1078-0432.CCR-23-2975","volume":"30","author":"C Guarducci","year":"2024","unstructured":"Guarducci, C. et al. Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor-positive breast cancer. Clin. Cancer Res. 30, 1889\u20131905 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1517_CR263","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1158\/0008-5472.CAN-25-0450","volume":"86","author":"YE Stern","year":"2026","unstructured":"Stern, Y. E. et al. Targeting CDK12\/13 drives mitotic arrest to overcome resistance to KRASG12C inhibitors. Cancer Res. 86, 485\u2013502 (2026).","journal-title":"Cancer Res."},{"key":"1517_CR264","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.cell.2009.05.047","volume":"138","author":"DC Hargreaves","year":"2009","unstructured":"Hargreaves, D. C., Horng, T. & Medzhitov, R. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 138, 129\u2013145 (2009).","journal-title":"Cell"},{"key":"1517_CR265","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/jcmm.13414","volume":"22","author":"H Hong","year":"2018","unstructured":"Hong, H. et al. CDK7 inhibition suppresses rheumatoid arthritis inflammation via blockage of NF-kB activation and IL-1b\/IL-6 secretion. J. Cell. Mol. Med. 22, 1292\u20131301 (2018).","journal-title":"J. Cell. Mol. Med."},{"key":"1517_CR266","doi-asserted-by":"publisher","first-page":"e337","DOI":"10.1016\/S2665-9913(21)00061-8","volume":"3","author":"AG Pratt","year":"2021","unstructured":"Pratt, A. G. et al. Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-findng, phase 1b trial. Lancet Rheumatol. 3, e337\u2013e346 (2021).","journal-title":"Lancet Rheumatol."},{"key":"1517_CR267","doi-asserted-by":"publisher","first-page":"eads7152","DOI":"10.1126\/science.ads7152","volume":"390","author":"P Dabas","year":"2025","unstructured":"Dabas, P. et al. Direct targeting and regulation of RNA polymerase II by cell signaling kinases. Science 390, eads7152 (2025).","journal-title":"Science"},{"key":"1517_CR268","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003546","volume":"9","author":"X Bisteau","year":"2013","unstructured":"Bisteau, X. et al. CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4\/CDK2 interplay mediated by p21 phosphorylation at the restriction point. PLoS Genet. 9, e1003546 (2013).","journal-title":"PLoS Genet."},{"key":"1517_CR269","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.molcel.2013.04.003","volume":"50","author":"MM Schachter","year":"2013","unstructured":"Schachter, M. M. et al. A CDK7\u2013CDK4 T-loop phosphorylation cascade promotes G1 progression. Mol. Cell 50, 250\u2013260 (2013).","journal-title":"Mol. Cell"},{"key":"1517_CR270","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1846","volume":"3","author":"N Czudnochowski","year":"2012","unstructured":"Czudnochowski, N., Bosken, C. A. & Geyer, M. Serine-7 but not serine-5 phosphorylation primes RNA polymerase II CTD for P-TEFb recognition. Nat. Commun. 3, 842 (2012).","journal-title":"Nat. Commun."},{"key":"1517_CR271","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15231","volume":"8","author":"B Portz","year":"2017","unstructured":"Portz, B. et al. Structural heterogeneity in the intrinsically disordered RNA polymerase II C-terminal domain. Nat. Commun. 8, 15231 (2017).","journal-title":"Nat. Commun."},{"key":"1517_CR272","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15233","volume":"8","author":"EB Gibbs","year":"2017","unstructured":"Gibbs, E. B. et al. Phosphorylation induces sequence-specific conformational switches in the RNA polymerase II C-terminal domain. Nat. Commun. 8, 15233 (2017).","journal-title":"Nat. Commun."},{"key":"1517_CR273","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.48725","volume":"8","author":"JE Mayfield","year":"2019","unstructured":"Mayfield, J. E. et al. Tyr1 phosphorylation promotes phosphorylation of Ser2 on the C-terminal domain of eukaryotic RNA polymerase II by P-TEFb. eLife 8, e48725 (2019).","journal-title":"eLife"},{"key":"1517_CR274","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1128\/MCB.24.2.787-795.2004","volume":"24","author":"K Fujinaga","year":"2004","unstructured":"Fujinaga, K. et al. Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element. Mol. Cell Biol. 24, 787\u2013795 (2004).","journal-title":"Mol. Cell Biol."},{"key":"1517_CR275","doi-asserted-by":"publisher","first-page":"210381","DOI":"10.1098\/rsob.210381","volume":"12","author":"R D\u00fcster","year":"2022","unstructured":"D\u00fcster, R., Ji, Y., Pan, K. T., Urlaub, H. & Geyer, M. Functional characterization of the human CDK10\/cyclin Q complex. Open Biol. 12, 210381 (2022).","journal-title":"Open Biol."},{"key":"1517_CR276","doi-asserted-by":"publisher","first-page":"eadf8698","DOI":"10.1126\/sciadv.adf8698","volume":"9","author":"M Qiu","year":"2023","unstructured":"Qiu, M. et al. CDK12 and Integrator\u2013PP2A complex modulates LEO1 phosphorylation for processive transcription elongation. Sci. Adv. 9, eadf8698 (2023).","journal-title":"Sci. Adv."},{"key":"1517_CR277","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493\u2013500 (2024).","journal-title":"Nature"},{"key":"1517_CR278","doi-asserted-by":"publisher","first-page":"W320","DOI":"10.1093\/nar\/gku316","volume":"42","author":"X Robert","year":"2014","unstructured":"Robert, X. & Gouet, P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 42, W320\u2013W324 (2014).","journal-title":"Nucleic Acids Res."},{"key":"1517_CR279","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jmb.2007.05.022","volume":"372","author":"E Krissinel","year":"2007","unstructured":"Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774\u2013797 (2007).","journal-title":"J. Mol. Biol."},{"key":"1517_CR280","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46375-9","volume":"15","author":"VI Cushing","year":"2024","unstructured":"Cushing, V. I. et al. High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design. Nat. Commun. 15, 2265 (2024).","journal-title":"Nat. Commun."},{"key":"1517_CR281","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/0092-8674(85)90117-5","volume":"42","author":"LA Allison","year":"1985","unstructured":"Allison, L. A., Moyle, M., Shales, M. & Ingles, C. J. Extensive homology among the largest subunits of eukaryotic and prokaryotic RNA polymerases. Cell 42, 599\u2013610 (1985).","journal-title":"Cell"},{"key":"1517_CR282","doi-asserted-by":"publisher","first-page":"7934","DOI":"10.1073\/pnas.82.23.7934","volume":"82","author":"JL Corden","year":"1985","unstructured":"Corden, J. L., Cadena, D. L., Ahearn, J. J. M. & Dahmus, M. E. A unique structure at the carboxyl terminus of the largest subunit of eukaryotic RNA polymerase II. Proc. Natl Acad. Sci. USA 82, 7934\u20137938 (1985).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1517_CR283","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1101\/gad.11.20.2622","volume":"11","author":"Y Zhu","year":"1997","unstructured":"Zhu, Y. et al. Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro. Genes Dev. 11, 2622\u20132632 (1997).","journal-title":"Genes Dev."},{"key":"1517_CR284","first-page":"149","volume":"1","author":"JM Lee","year":"1991","unstructured":"Lee, J. M. & Greenleaf, A. L. CTD kinase large subunit is encoded by CTK1, a gene required for normal growth of Saccharomyces cerevisiae. Gene Expr. 1, 149\u2013167 (1991).","journal-title":"Gene Expr."},{"key":"1517_CR285","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/374193a0","volume":"374","author":"S-M Liao","year":"1995","unstructured":"Liao, S.-M. et al. A kinase\u2013cyclin pair in the RNA polymerase II holoenzyme. Nature 374, 193\u2013196 (1995).","journal-title":"Nature"},{"key":"1517_CR286","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S0092-8674(88)91087-2","volume":"54","author":"AE Rougvie","year":"1988","unstructured":"Rougvie, A. E. & Lis, J. T. The RNA polymerase II molecule at the 5\u2019 end of the uninduced hspTO gene of D. melanogaster is transcriptionally engaged. Cell 54, 795\u2013804 (1988).","journal-title":"Cell"},{"key":"1517_CR287","doi-asserted-by":"publisher","first-page":"5285","DOI":"10.1128\/mcb.11.10.5285-5290.1991","volume":"11","author":"T O\u2019Brien","year":"1991","unstructured":"O\u2019Brien, T. & Lis, J. T. RNA polymerase II pauses at the 5\u2019 end of the transcriptionally induced Drosophila hsp70 gene. Mol. Cell. Biol. 11, 5285\u20135290 (1991).","journal-title":"Mol. Cell. Biol."},{"key":"1517_CR288","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.molcel.2009.02.018","volume":"33","author":"H Qiu","year":"2009","unstructured":"Qiu, H., Hu, C. & Hinnebusch, A. G. Phosphorylation of the Pol II CTD by KIN28 enhances BUR1\/BUR2 recruitment and Ser2 CTD phosphorylation near promoters. Mol. Cell 33, 752\u2013762 (2009).","journal-title":"Mol. Cell"},{"key":"1517_CR289","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.molcel.2009.01.029","volume":"33","author":"L Viladevall","year":"2009","unstructured":"Viladevall, L. et al. TFIIH and P-TEFb coordinate transcription with capping enzyme recruitment at specific genes in fission yeast. Mol. Cell 33, 738\u2013751 (2009).","journal-title":"Mol. Cell"},{"key":"1517_CR290","doi-asserted-by":"publisher","first-page":"7395","DOI":"10.1093\/emboj\/17.24.7395","volume":"17","author":"T Wada","year":"1998","unstructured":"Wada, T., Takagi, T., Yamaguchi, Y., Watanabe, D. & Handa, H. Evidence that P-TEFb alleviates the negative effect of DSIF on RNA polymerase II-dependent transcription in vitro. EMBO J. 17, 7395\u20137403 (1998).","journal-title":"EMBO J."},{"key":"1517_CR291","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/35104581","volume":"414","author":"VT Nguyen","year":"2001","unstructured":"Nguyen, V. T., Kiss, T., Michels, A. A. & Bensaude, O. 7SK small nuclear RNA binds to and inhibits the activity of CDK9\/cyclin T complexes. Nature 414, 322\u2013325 (2001).","journal-title":"Nature"},{"key":"1517_CR292","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.molcel.2010.01.026","volume":"37","author":"C Lin","year":"2010","unstructured":"Lin, C. et al. AFF4, a component of the ELL\/P\u2013TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol. Cell 37, 429\u2013437 (2010).","journal-title":"Mol. Cell"},{"key":"1517_CR293","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26935-z","volume":"12","author":"IH Kaltheuner","year":"2021","unstructured":"Kaltheuner, I. H. et al. Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation. Nat. Commun. 12, 6607 (2021).","journal-title":"Nat. Commun."},{"key":"1517_CR294","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1747-0285.2009.00905.x","volume":"75","author":"T Zhou","year":"2010","unstructured":"Zhou, T. et al. Structural analysis of DFG-in and DFG-out dual Src\u2013Abl inhibitors sharing a common vinyl purine template. Chem. Biol. Drug Des. 75, 18\u201328 (2010).","journal-title":"Chem. Biol. Drug Des."},{"key":"1517_CR295","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/1535-7163.MCT-15-0617","volume":"15","author":"IC Waizenegger","year":"2016","unstructured":"Waizenegger, I. C. et al. A novel RAF kinase inhibitor with DFG-out-binding mode: high efficacy in BRAF-mutant tumor xenograft models in the absence of normal tissue hyperproliferation. Mol. Cancer Ther. 15, 354\u2013365 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"1517_CR296","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1021\/acsmedchemlett.9b00381","volume":"10","author":"DJH De Clercq","year":"2019","unstructured":"De Clercq, D. J. H. et al. Discovery and optimization of dibenzodiazepinones as allosteric mutant-selective EGFR inhibitors. ACS Med. Chem. Lett. 10, 1549\u20131553 (2019).","journal-title":"ACS Med. Chem. Lett."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01517-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01517-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01517-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:02:17Z","timestamp":1793278937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01517-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":296,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1517"],"URL":"https:\/\/doi.org\/10.1038\/s41573-026-01517-0","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"16 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}